Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02589600 · ClinicalTrials.gov registry record · Phase 4
Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
A Phase 4 study, sponsored by Susan L. Greenspan.
- Completed
- Registry status
- Phase 4
- Development phase
- 310
- Enrollment target
NCT02589600 is a Phase 4 study that has completed, run by Susan L. Greenspan. The registered enrollment target is 310 participants.
The verdict
NCT02589600, a Phase 4 study, has completed, sponsored by Susan L. Greenspan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 310 participants
- Enrollment target
Study Summary
The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
Interventions
- OTHER Saline
- DRUG Zoledronic acid
- DIETARY_SUPPLEMENT vitamin D
- DIETARY_SUPPLEMENT calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2016-01 |
| Est. Completion | 2022-06-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02589600
The ClinicalTrials.gov registry entry for NCT02589600 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susan L. Greenspan, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT02589600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02589600 about?
NCT02589600 is a clinical study titled "Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)". The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
What is the current status of trial NCT02589600?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 310 participants. The study started on 2016-01. Estimated completion is 2022-06-22.
What interventions are being tested in trial NCT02589600?
The interventions under investigation include: Saline (OTHER), Zoledronic acid (DRUG), vitamin D (DIETARY_SUPPLEMENT), calcium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02589600?
This trial is sponsored by Susan L. Greenspan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.